[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)].
Inatomi
Nobuhiro
N
Inatomi_Nobuhiro@takeda.co.jp
Nitta
Katsuyuki
K
Sakurai
Yuichi
Y
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D005744:Gastric Acid / Q000502:physiology; D005753:Gastric Mucosa / Q000187:drug effects; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006801:Humans; D064747:Lansoprazole; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole